<DOC>
	<DOCNO>NCT02593175</DOCNO>
	<brief_summary>The goal clinical research study learn receive 4 cycle experimental chemotherapy combination surgery help shrink slow growth tumor remove surgery . The safety combination also study .</brief_summary>
	<brief_title>Women 's Triple-Negative First-Line Study : A Phase II Trial Panitumumab , Carboplatin Paclitaxel ( PaCT ) Patients With Localized Triple-Negative Breast Cancer ( TNBC ) With Tumors Predicted Insensitive Standard Neoadjuvant Chemotherapy</brief_title>
	<detailed_description>Study Drug Administration : About 1 week Cycle 1 , find eligible take part study , receive single dose panitumumab vein 1 hour . You receive study drug combination 4 cycle . Each cycle 21 day . On Day 1 Cycle , receive panitumumab , carboplatin , paclitaxel vein . Panitumumab give 30-60 minute , paclitaxel 2 hour , carboplatin 2 hour . On Days 8 15 cycle , receive panitumumab paclitaxel vein follow time Day 1 . If side effect , study doctor may decide low study drug dose ( ) stop take drug ( ) . You may able restart study drug ( ) later low dose . The study doctor discus . Study Visits : About 1 week Cycle 1 , day receive single dose Panitumumab , blood drawn ( 2 teaspoon ) pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point . About 1 week first panitumumab dose , blood drawn ( 2 teaspoon ) PK test . On Day 1 cycle : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . On Days 8 15 cycle , blood ( 2 teaspoon ) draw routine test . On Day 21 ( +/- 1 day ) Cycle 2 , blood ( 2 teaspoon ) draw PK test . Surgery : After receive 4 cycle chemotherapy , time disease appear get bad , MRI , mammogram , ultrasound check status disease . Based scan , doctor decide type surgery remove tumors.You give separate surgery consent form describe procedure risk . If come study , may offer chemotherapy , surgery , another option . At time surgery , blood ( 2 teaspoon ) draw PK test . Length Treatment : You may receive 4 cycle chemotherapy . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study least 2 year surgery . Follow-Up : Every 3-4 month , study team track standard care physical exam visit . This investigational study . Paclitaxel carboplatin FDA approve commercially available treatment breast cancer . Panitumumab FDA approve commercially available treatment colorectal cancer . It currently use research purpose breast cancer setting . The study doctor explain study drug design work . Up 37 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must intact evaluable primary tumor biopsy proven axillary node involvement least 1.0 cm small dimension base image neoadjuvant anthracyclinebased chemotherapy prior initiation neoadjuvant chemotherapy protocol . Baseline measurement evaluation must obtain within 4 week registration study . All area disease record order ass response uniformity response therapy . 2 . Triplenegative breast cancer define ER &lt; 10 % ; PR &lt; 10 % immunohistochemistry ( IHC ) HER2 01+ IHC 2+ , FISH &lt; 2 , gene copy number &lt; 4 . 3 . Age &gt; /= 18 year . 4 . Patients must ECOG performance status 0 1 . 5 . Patients must receive least one dose anthracycline base neoadjuvant regimen . Patients eligible therapy discontinue due disease progression therapy intolerance . 6 . Baseline MUGA echocardiogram show LVEF &gt; /= 50 % within 6 week prior initiation neoadjuvant chemotherapy . 7 . 7 ) Adequate organ function define follow parameter • Serum creatinine &lt; /= 1.5 mg/dl . Creatinine clearance ( CrCl ) &gt; /= 50 mL/min calculate CockcroftGault method follow : male creatinine clearance = ( 140 age year ) x ( weight kg ) / ( serum Cr x 72 ) ; Female CrCl = ( 140 age year ) x ( weight kg ) x 0.85 / ( serum Cr x 72 ) . • ANC &gt; /= 1500/mm^3 , platelet &gt; /= 100,000/mm^3 • Hemoglobin &gt; /=9.0 g/dL • SGOT ( AST ) SGPT ( ALT ) &lt; 3.0 x upper limit normal • Alkaline phosphatase ( Alp ) &lt; /= 2.5 x ULN • Total bilirubin &lt; /=1.5 x ULN 8 . Signed informed consent . 1 . Patient unwilling unable sign date IRB approve informed consent . 2 . Patients less 1.0 cm measurable residual disease neoadjuvant anthracycline base chemotherapy . 3 . Women pregnant lactating . 4 . Patients history prior malignancy within 5 year study entry exception curatively treat nonmelanomatous skin cancer carcinoma situ cervix breast . 5 . Patients history stage IV metastatic disease . 6 . Any serious medical illness , treat study , would limit survival le 1 month psychiatric illness would limit informed consent . 7 . Known positive test ( ) human immunodeficiency virus infection , hepatitis C virus , acute chronic active hepatitis B infection . 8 . Patients peripheral neuropathy &gt; grade 1 . 9 . Patients history serious cardiac event define : New York Heart Association class 3 4 heart failure , history myocardial infarction , unstable angina CVA within 6 month protocol registration . 10 . Patients history PR prolongation AV block . 11 . Patients history prior therapy paclitaxel and/or carboplatin . 12 . Patients receive cumulative dose doxorubicin great 360 mg/m^2 epirubicin great 640 mg/m^2 . 13 . Patients concurrently use hormonal therapy and/or concurrent radiation therapy . 14 . Patients prior radiation therapy primary breast carcinoma axillary lymph node . 15 . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , must use highly effective method contraception study 8 week . Highly effective contraception method include combination two following : • Placement intrauterine device ( IUD ) intrauterine system ( IUS ) ; • Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/ vaginal suppository ; • Total abstinence ; • Male/female sterilization . 16 . Continued # 15 : Women consider postmenopausal childbearing potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider childbearing potential . 17 . Male patient whose sexual partner ( ) WOCBP willing use adequate contraception , study 8 week end treatment . 18 . Negative serum urine pregnancy test woman within 72 hour receive first dose study medication woman childbearing potential .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Triple-Negative Breast Cancer</keyword>
	<keyword>TNBC</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Biopsy</keyword>
	<keyword>Fine-needle aspiration</keyword>
	<keyword>FNA</keyword>
</DOC>